• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCOVID-19 vaccines

47.6% of U.S. adults have gotten a COVID vaccine. See how your state is doing

By
Erika Fry
Erika Fry
and
Nicolas Rapp
Nicolas Rapp
Down Arrow Button Icon
By
Erika Fry
Erika Fry
and
Nicolas Rapp
Nicolas Rapp
Down Arrow Button Icon
April 14, 2021, 6:43 PM ET

America’s otherwise smooth coronavirus vaccine rollout took a dramatic turn this week, with the abrupt pause in the use of Johnson & Johnson’s COVID shot due to concerns about extremely rare blood clotting incidents. President Joe Biden said yesterday the development would not slow the nation’s vaccine drive. Even so, with the Centers for Disease Control and Prevention meeting with J&J today about the fate of that vaccine, and new cases of COVID on the rise due to the spread of more contagious variant strains, the ongoing distribution of Moderna and Pfizer’s two-shot vaccines takes on even greater urgency. 

The good news is many people already have some protection against the virus. As of April 14, 123.9 million Americans have received at least one dose of a COVID vaccine, according to data from the CDC. That group, up from 110 million people last week, includes 79.6% of individuals over the age of 65, 47.6% of people over the age of 18, and 37.3% of the total population. Nearly 76.7 million Americans, or 23.1% of the population, have been fully vaccinated.

In total, the country has administered 194.8 million vaccines. The vast majority of those have been doses of the Pfizer and Moderna vaccines; J&J’s shot accounts for 7.5 million of administered doses.

The share of people vaccinated in each state varies widely across the country, from 28.4% in Mississippi having received at least one dose to 53.9% in New Hampshire. California, the most populous state, has administered the most vaccines—23.7 million—and reached 40% of its population.

Reports from Europe, which has struggled with its rollout, in part due to similar concerns of extremely rare blood clotting incidents involving the AstraZeneca vaccine, suggest the EU may prioritize the purchase of mRNA vaccines going forward. Meanwhile, as Russia’s COVID vaccine, Sputnik, racks up approvals around the world, its limited use in Europe is a subject of some controversy.

Share of the population that has received at least once shot

State or territoryShare vaccinated
Alaska38.8%
Alabama29.1%
Arkansas32.0%
Arizona35.8%
California40.0%
Colorado39.5%
Connecticut45.7%
District of Columbia37.4%
Delaware39.3%
Florida35.5%
Georgia31.0%
Guam40.3%
Hawaii37.7%
Iowa38.9%
Idaho30.9%
Illinois39.2%
Indiana31.3%
Kansas38.3%
Kentucky37.1%
Louisiana30.1%
Massachusetts45.3%
Maryland40.1%
Maine45.9%
Michigan36.1%
Minnesota40.0%
Missouri32.2%
Mississippi28.4%
Montana36.7%
North Carolina34.7%
North Dakota37.0%
Nebraska38.9%
New Hampshire53.9%
New Jersey43.5%
New Mexico45.4%
Nevada34.4%
New York40.4%
Ohio36.1%
Oklahoma35.8%
Oregon36.4%
Pennsylvania40.7%
Puerto Rico28.1%
Rhode Island42.1%
South Carolina33.1%
South Dakota41.6%
Tennessee30.6%
Texas33.4%
Utah33.7%
Virginia39.9%
Virgin Islands28.6%
Vermont43.9%
Washington38.1%
Wisconsin40.2%
West Virginia33.9%
Wyoming31.7%
About the Authors
Erika Fry
By Erika Fry
LinkedIn iconTwitter icon
See full bioRight Arrow Button Icon
Nicolas Rapp
By Nicolas RappInformation Graphics Director
LinkedIn icon

Nicolas Rapp is the former information graphics director at Fortune.

See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.